Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial

@article{Bller2012EnoxaparinFB,
  title={Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial},
  author={Harry R B{\"u}ller and Alexander A. S. Gallus and G{\'e}rard Pillion and Martin H. Prins and Gary E. Raskob},
  journal={The Lancet},
  year={2012},
  volume={379},
  pages={123-129}
}

Figures and Tables from this paper

Oral Rivaroxaban Versus Standard Therapy in Acute Venous Thromboembolism Treatment for Vietnamese Patients

The finding of this study in Vietnamese patients with acute VTE presented comparable EAS profile with RIV versus STDT, consistent with those found in global population.

Treatment of venous thromboembolism: the single-drug approach.

Rivaroxaban and apixaban are the only ones to date for which there is persuasive evidence coming from randomized clinical trials in support of the ‘single-drug’ approach for the treatment of both patients with deep vein thrombosis and those with hemodynamically stable pulmonary embolism.

Pentasaccharides for the treatment of deep vein thrombosis.

Five randomised controlled trials in which people 18 years of age or older with a DVT confirmed by standard imaging techniques were allocated to receive a pentasaccharide for the treatment of DVT in comparison with standard therapy or other treatments showed moderate to very low quality evidence.

Bioequipotency of idraparinux and idrabiotaparinux after once weekly dosing in healthy volunteers and patients treated for acute deep vein thrombosis.

Pharmacodynamic parameters reported after single dose in healthy volunteers and after repeated once weekly dosing in patients demonstrated the bioequipotency of idrabiotaparinux and idraparinux based on FXa inhibition.

Intracerebral bleeding in patients on antithrombotic agents.

The current concept of emergency treatment in OAC-ICH is rapid restoration of effective coagulation using hemostatic factors such as prothrombin complex concentrate, fresh frozen plasma, factor IX concentrates, and recombinant factor VIIa in addition to vitamin K.

Newer Anticoagulants in Cardiovascular Disease: A Systematic Review of the Literature

Novel anticoagulants targeting inhibition of factor Xa and thrombin (factor IIa) have now been incorporated into clinical practice based on the results of large randomized clinical trials, with the recent U.S. Food and Drug Administration approval of dabigatran for stroke prevention in atrial fibrillation and rivaroxaban for deep vein thrombosis and stroke prevention for these and other indications.

Management of venous thromboembolism : an update

The phase 3 trial programme of new oral anticoagulants in the treatment of venous thrombo-embolism has been completed, and the results indicate that these agents are at least as effective and probably cause less major bleeding than currently standard treatment.

Recent pharmacological advances for treating venous thromboembolism: are we witnessing the demise of warfarin?

The current practice with its limitations and pitfalls is discussed, important trials that have launched new oral anticoagulants into clinical practice are reviewed, and new factor Xa and direct thrombin inhibitors are being introduced intoclinical practice that fulfil some of these aims.

Pentasaccharides for the prevention of venous thromboembolism.

In people who require anticoagulant treatment to prevent venous thromboprophylaxis, analyses indicated that fondaparinux reduced total VTE and DVT and RR 0.55, 95% CI 0.42 to 0.73, as well as better tolerated than unfractionated heparin, LMWH and warfarin.
...

References

SHOWING 1-10 OF 20 REFERENCES

Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

For the treatment of acute venous thromboembolism, a fixed dose of dabigatran is as effective as warfarin, has a safety profile that is similar to that of warfar in, and does not require laboratory monitoring.

Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis.

Patients with proximal-vein thrombosis require initial treatment with full-dose heparin, which can safely be combined with acenocoumarol therapy, and major bleeding complications were infrequent and comparable in the two groups.

The pharmacokinetics of idraparinux, a long‐acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials

The particular characteristics of idraparinux – rapid onset of action and long‐acting anticoagulant effect – offer interesting clinical perspectives currently under investigation with idrabiotaparinux, the reversible biotinylated form of idrasaccharide.

The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. The emerging theme of delayed recurrence.

It is demonstrated that the initial heparin treatment affects the long-term clinical outcome when these data are analyzed for each individual study by treatment group, observed difference in outcome, and pooled analysis.

Extended Oral Anticoagulant Therapy after a First Episode of Pulmonary Embolism

A multicenter randomized trial to evaluate the long-term clinical benefit of extending a 3-month course of oral anticoagulant therapy to 6 months or to 1 year in patients with a first episode of pulmonary embolism.

Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

This article discusses the management of venous thromboembolism (VTE) and thrombophilia, as well as the use of antithrombotic agents, during pregnancy and is part of the American College of Chest

Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

This chapter about treatment for venous thromboembolic disease is part of the American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) and indicates that the benefits do or do not outweigh risks, burden, and costs.

The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

The article describes the antithrombotic effect ofVKAs, the monitoring of anticoagulation intensity, the clinical applications of VKA therapy, and the optimal therapeutic range of VKAs, and provides specific management recommendations.

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

This article describes the antithrombotic effect of the VKAs, the monitoring of anticoagulation intensity, and the clinical applications of VKA therapy and provides specific management recommendations.